115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
中成药治疗慢性前列腺炎/慢性盆腔疼痛综合征的比较有效性：贝叶斯网络 Meta 分析
Authors Lin S, Huang W, Liu R, Xu J, Li Y
Received 19 August 2025
Accepted for publication 23 December 2025
Published 14 January 2026 Volume 2026:19 560430
DOI https://doi.org/10.2147/JPR.S560430
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor King Hei Stanley Lam
Shuai Lin,1,2,* Wenrui Huang,3,* Ruxin Liu,2 Juan Xu,2 Yanlin Li2
1Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong, People’s Republic of China; 2Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, Guangdong, People’s Republic of China; 3Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yanlin Li, Email 20232120283@stu.gzucm.edu.cn Juan Xu, Email 260119441@qq.com
Objective: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) presents with persistent pelvic pain, urinary symptoms, and psychological burden, severely affecting patients’ quality of life. While antibiotics and α-blockers are commonly prescribed, their long-term efficacy is limited and adverse reactions are frequent. Chinese patent medicines (CPMs) have emerged as promising alternatives, yet the lack of head-to-head evidence among formulations hinders evidence-based clinical recommendations.
Methods: Eight databases—CNKI, WanFang, VIP, SinoMed, PubMed, Web of Science, Embase, and the Cochrane Library—were searched from inception to November 1, 2025. Randomized controlled trials enrolling adults with CP/CPPS treated with CPMs versus standard therapy (ST) were included. Bias was assessed with ROB 2, and evidence certainty with CINeMA. A Bayesian network meta-analysis was performed, and outcomes were summarized using forest plots, league tables, and SUCRA curves in RStudio.
Results: Seventy-six trials (n=8431) involving 12 CPMs were analyzed. All studies were conducted in China, and all CPMs outperformed ST in enhancing the total effective rate and reducing NIH-CPSI scores. Shuangshi Tonglin Capsules (SSTL) ranked highest for both overall efficacy (OR = 5.6; 95% CI [2.0, 17]; SUCRA 73.8%) and NIH-CPSI reduction (MD = − 8.0; 95% CI [− 11, − 4.8]; SUCRA 93.3%). SSTL also provided the largest improvements in pain (MD = − 5.4; 95% CI [− 8.0, − 2.8]) and quality of life (MD = − 4.3; 95% CI [− 5.7, − 2.9]).
Conclusion: Compared with ST, CPMs significantly improved CP/CPPS symptoms, with SSTL showing the greatest overall benefit. However, since all included studies originated from China, the generalizability of these findings to other populations may be limited.
Keywords: chronic prostatitis, chronic pelvic pain syndrome, Chinese patent medicines, network meta-analysis
1Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, Guangdong, People’s Republic of China; 2Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, Guangdong, People’s Republic of China; 3Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yanlin Li, Email 20232120283@stu.gzucm.edu.cn Juan Xu, Email 260119441@qq.com
Objective: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) presents with persistent pelvic pain, urinary symptoms, and psychological burden, severely affecting patients’ quality of life. While antibiotics and α-blockers are commonly prescribed, their long-term efficacy is limited and adverse reactions are frequent. Chinese patent medicines (CPMs) have emerged as promising alternatives, yet the lack of head-to-head evidence among formulations hinders evidence-based clinical recommendations.
Methods: Eight databases—CNKI, WanFang, VIP, SinoMed, PubMed, Web of Science, Embase, and the Cochrane Library—were searched from inception to November 1, 2025. Randomized controlled trials enrolling adults with CP/CPPS treated with CPMs versus standard therapy (ST) were included. Bias was assessed with ROB 2, and evidence certainty with CINeMA. A Bayesian network meta-analysis was performed, and outcomes were summarized using forest plots, league tables, and SUCRA curves in RStudio.
Results: Seventy-six trials (n=8431) involving 12 CPMs were analyzed. All studies were conducted in China, and all CPMs outperformed ST in enhancing the total effective rate and reducing NIH-CPSI scores. Shuangshi Tonglin Capsules (SSTL) ranked highest for both overall efficacy (OR = 5.6; 95% CI [2.0, 17]; SUCRA 73.8%) and NIH-CPSI reduction (MD = − 8.0; 95% CI [− 11, − 4.8]; SUCRA 93.3%). SSTL also provided the largest improvements in pain (MD = − 5.4; 95% CI [− 8.0, − 2.8]) and quality of life (MD = − 4.3; 95% CI [− 5.7, − 2.9]).
Conclusion: Compared with ST, CPMs significantly improved CP/CPPS symptoms, with SSTL showing the greatest overall benefit. However, since all included studies originated from China, the generalizability of these findings to other populations may be limited.
Keywords: chronic prostatitis, chronic pelvic pain syndrome, Chinese patent medicines, network meta-analysis